IMpact of therapY using coleSevelam treatment reducing bile acids in patients with fonTan cIrCulation (MYSTIC): Rationale and study design
NCT06197763 This manuscript describes the rationale and design of the MYSTIC study, which to our knowledge is the first interventional trial targeting a Fontan-specific metabolic derangement. The results will inform the feasibility of BA sequestration therapy in Fontan patients and guide future larger studies aimed at improving outcomes in this growing high-risk population.
Authors
- Heather Armstrong (ORCID: https://orcid.org/0000-0003-3991-9201)
- Keivan Alizadeh
- James W. Tam (ORCID: https://orcid.org/0000-0001-5712-7756)
- Sanjiv Dhingra (ORCID: https://orcid.org/0000-0002-2664-7633)
- Aleisha Reimer (ORCID: https://orcid.org/0000-0002-1706-7936)
- Ashish H. Shah (ORCID: https://orcid.org/0000-0002-9396-7178)
- Amir Ravandi
- Robin Ducas (ORCID: https://orcid.org/0000-0002-1356-1646)
- Setor K. Kunutsor (ORCID: https://orcid.org/0000-0002-2625-0273)
- Ishika Mittal
Institutions
- St. Boniface Hospital (CA)
- Canadian Science Centre for Human and Animal Health (CA)
- Canadian Veterinary Medical Association (CA)
- Universidade de Uberaba (BR)
- University of Manitoba (CA)
Publication Details
- Journal
- American Heart Journal
- Published
- 2025-08-19
- DOI
- https://doi.org/10.1016/j.ahj.2025.08.011
- Citations
- 6
- Primary Topic
- Pediatric Hepatobiliary Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 12.04
Funders
- University of Manitoba
- Max Rady College of Medicine, University of Manitoba